UTHR News and Press, United Therapeutics Corporation From 05/01/24

2024-05-01 06:37:13 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quar...

2024-04-30 11:53:23 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 Please replace the photo for release dated April 24, 2024 wi...

2024-04-24 10:23:46 ET More on United Therapeutics United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects United Therapeutics Corporation (UTHR) Q4 2023 Earnings Call Transcript United Therapeutics Corporation 2023 Q4 - Results ...

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 United Therapeutics Corporation (Nasdaq: UTHR ), a publi...

United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. ...

Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion session An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fib...

2024-03-31 08:00:00 ET More on Liquidia Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript Liquidia Corporation: A Complicated Tale Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices Liquidia gains after court win in pat...

2024-03-28 16:24:45 ET Read the full article on Seeking Alpha For further details see: Liquidia gains after court win in patent dispute with United Therapeutics